Molecular mechanism of the therapy-related myeloid neoplasms

我们分析了治疗相关髓系肿瘤(t-MN)患者的遗传异常，发现VP16治疗后t-MN中最常见的分子异常是RUNX1或MLL基因异常。VP16处理的细胞在RUNX1和MLL基因上都显示出重排条带，这表明它可能导致t-MN的后续发展。此外，我们还证实了RUNX1突变体与BMI1过表达在t-MDS/AML的发生中存在协同作用。

We analyzed genetic abnormalities in the patients with therapy-related myeloid neoplasms (t-MN), and found that gene abnormalities of RUNX1 orMLL gene were the most common molecular abnormalities in t-MN after acute promyelocytic leukemia treated with VP16. VP16-treated cells showed rearrangement bands in both RUNX1 and MLL genes, suggesting that it may result in subsequent development of t-MN. Furthermore, we verified that RUNX1 mutant collaborates with BMI1 overexpression in the development of t-MDS/AML.